Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | FLT3 | P36888 | 1/20 | 0.57 |
| ▸ | CNR2 | P34972 | 16/20 | 0.55 |
| ▸ | CNR1 | P21554 | 12/20 | 0.55 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CSF1R | P07333 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13284926 | 1.00 | NPC1 (0.60) | NPC1SMN1; SMN2FLT3CNR2CNR1 | |
| SCHEMBL13256816 | 0.96 | NPC1 (0.59) | NPC1SMN1; SMN2FLT3CNR2CNR1 | |
| SCHEMBL13257165 | 0.96 | NPC1 (0.59) | NPC1SMN1; SMN2FLT3CNR2CNR1 | |
| SCHEMBL13257167 | 0.96 | NPC1 (0.59) | NPC1SMN1; SMN2FLT3CNR2CNR1 | |
| SCHEMBL13257193 | 0.95 | NPC1 (0.58) | NPC1SMN1; SMN2FLT3CNR2CNR1 | |
| SCHEMBL9892851 | 0.93 | NPC1 (0.61) | NPC1SMN1; SMN2FLT3CNR2CNR1 | |
| SCHEMBL13257838 | 0.84 | NPC1 (0.54) | NPC1SMN1; SMN2FLT3CNR2CNR1 | |
| SCHEMBL13256811 | 0.84 | NPC1 (0.54) | NPC1SMN1; SMN2FLT3CNR2CNR1 | |
| SCHEMBL13257836 | 0.82 | NPC1 (0.55) | NPC1SMN1; SMN2FLT3CNR2CNR1 | |
| SCHEMBL13256772 | 0.81 | FLT3 (0.65) | NPC1SMN1; SMN2FLT3CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2384320-B1 | PYRROLIDINE COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INT (DE) | 2015-03-04 | — | — | EP | disclosed |
| US-8629157-B2 | Pyrrolidine compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-14 | — | — | US | disclosed |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
| EP-2384320-A2 | PYRROLIDINE COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | Boehringer Ingelheim International GmbH (DE) | 2011-11-09 | — | — | EP | disclosed |
| WO-2010077836-A2 | PYRROLIDINE COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | NPC1 1904/4885SMN1; SMN2 4659/4885FLT3 2116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.